Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,319 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Targeted agent Clear all
Withdrawn Phase 4 Interventional

Comparative Effectiveness Study of MIST Therapy Versus Negative Pressure Wound Therapy

NCT01200563
View directory record Official record
Conditions
Wounds
Interventions
MIST Therapy, Vacuum Assisted Closure, MIST Therapy and Negative Pressure Wound Therapy
Device
Lead sponsor
Celleration, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 31, 2026, 5:20 AM EDT
Not yet recruiting Phase 2 Interventional

Targeting Interferon Gamma With Emapalumab to Lung Transplant Recipients With Interferon Gamma-high Acute Lung Allograft Dysfunction

NCT07538336
View directory record Official record
Conditions
Lung Transplant
Interventions
Emapalumab, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 31, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional Results available

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

NCT01116232
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, rituximab, sirolimus, tacrolimus, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, management of therapy complications, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 31, 2026, 5:20 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Impact of a Novel Brain Longevity Supplement Containing the Postbiotic Urolithin A (Mitopure) on Cognitive Function and Related Health Outcomes

NCT07060898
View directory record Official record
Conditions
Aging, Cognitive Decline, Brain Fog, Cognitive Function
Interventions
Active Product, Placebo Product
Dietary Supplement
Lead sponsor
Amazentis SA
Industry
Eligibility
40 Years and older
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 31, 2026, 5:20 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Promoting Healthier Food Purchases By Leveraging the Online-Grocery Environment

NCT02489396
View directory record Official record
Conditions
Obesity
Interventions
Nutrition facts automatically or not automatically displayed, Nutrition facts in color, Nutrition Facts Label in Larger Font, Healthier Items First
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 31, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

NCT05005845
View directory record Official record
Conditions
Cutaneous Neurofibroma, Neurofibromatosis 1
Interventions
NFX-179 gel, Vehicle gel
Drug
Lead sponsor
NFlection Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Fremont, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 31, 2026, 5:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

NCT01943994
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 31, 2026, 5:20 AM EDT
Not yet recruiting Phase 2 Interventional

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

NCT07634094
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure
Drug · Biological · Procedure
Lead sponsor
Kalinski, Pawel, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 5:20 AM EDT
Withdrawn Phase 2 Interventional

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

NCT05456165
View directory record Official record
Conditions
Colonic Neoplasms, Colorectal Neoplasms
Interventions
GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Adjuvant chemotherapy
Drug
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Detroit, Michigan • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 31, 2026, 5:20 AM EDT
Not listed Phase 3 Interventional

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

NCT01204801
View directory record Official record
Conditions
Breast Cancer
Interventions
Focused Microwave Thermotherapy, Chemotherapy (control)
Device · Drug
Lead sponsor
Medifocus, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 31, 2026, 5:20 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

NCT04262154
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Atezolizumab, Abiraterone, Prednisone, GnRH analog, Stereotactic Body Radiotherapy (SBRT), Enzalutamide, Follow up
Drug · Radiation · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 5:20 AM EDT
Terminated No phase listed Observational

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

NCT04628871
View directory record Official record
Conditions
Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II
Interventions
SB-318, SB-913, SB-FIX
Biological
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Oakland, California • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 31, 2026, 5:20 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

NCT04939701
View directory record Official record
Conditions
Ovarian Cancer, NSCLC, ESCC, Solid Tumors
Interventions
ASP0739
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Duarte, California • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 31, 2026, 5:20 AM EDT
Withdrawn Not applicable Interventional

Higher Irradiance in Keratoconus Ectasia

NCT01789333
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
UVA Light with irradiance exposure of 9 mW/cm2, Riboflavin 0.1% ophthalmic solution
Device · Drug
Lead sponsor
Stephen Trokel
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 31, 2026, 5:20 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

NCT05094804
View directory record Official record
Conditions
Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Interventions
OR2805, Cemiplimab, Docetaxel
Drug
Lead sponsor
OncoResponse, Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 31, 2026, 5:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT07186842
View directory record Official record
Conditions
Advanced Solid Cancers
Interventions
BNT329, CA19-9-targeting monoclonal antibody
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Denver, Colorado • Orlando, Florida • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 5:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

RhinAer Procedure for Treatment of Chronic Rhinitis Study

NCT04533438
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
RhinAer Stylus, Sham
Device
Lead sponsor
Aerin Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
13
States / cities
Roseville, California • Torrance, California • Plantation, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 31, 2026, 5:20 AM EDT
Active, not recruiting Phase 2 Interventional

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

NCT05826964
View directory record Official record
Conditions
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, PI3K inhibitor + SERD, PI3K inhibitor + AI, Chemotherapy, Oral SERD, PARPi, AKT inhibitor, Step 3 Arm 2
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 31, 2026, 5:20 AM EDT
Completed Not applicable Interventional Results available

Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans

NCT00706901
View directory record Official record
Conditions
Alcohol Dependence, Dual Diagnosis, Drug Dependence
Interventions
Arm 1 GMI, Arm 2 IHMD, Arm 3 TCC
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 31, 2026, 5:20 AM EDT
Recruiting No phase listed Observational

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

NCT06599619
View directory record Official record
Conditions
Melanoma
Interventions
Single agent, adjuvant anti-PD1 therapy
Drug
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 31, 2026, 5:20 AM EDT
Withdrawn Phase 2 Interventional

D-Serine for Cocaine Dependence Pilot

NCT01715051
View directory record Official record
Conditions
Cocaine Dependence
Interventions
D-serine, Cognitive Behavioral Therapy, Placebo
Drug · Behavioral
Lead sponsor
Theresa Winhusen
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 31, 2026, 5:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

School-Based Treatment for Early Childhood Anxiety

NCT04811482
View directory record Official record
Conditions
Anxiety
Interventions
TCIT-CALM (Teacher-Child Interaction Training-CALM)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 7 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 31, 2026, 5:20 AM EDT
Recruiting Not applicable Interventional

Neuroimaging of Adolescent Cannabis Use Treatment

NCT07340554
View directory record Official record
Conditions
Cannabis Use, Cannabis Dependence, Cannabis Use Disorder, Cannabis Abuse, Cannabis Intoxication, Cannabis Smoking, Cannabis Withdrawal, Cannabis-Related Disorder, Cannabis Abuse, in Remission, Cannabis Abuse, Episodic Use, Marijuana, Marijuana Abuse, Marijuana Use, Marijuana Smoking, Marijuana Dependence, Marijuana User, Marijuana-Related Disorder, Marijuana Use Disorder, Addiction, Addiction, Substance, Substance Use, Substance Use Disorders, Substance Dependence, Substance Abuse, Substance Related Problem, Substance Abuse Drug Chronic
Interventions
Contingency Management, Elastic Net Regression
Behavioral · Device
Lead sponsor
Indiana University
Other
Eligibility
14 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 31, 2026, 5:20 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

NCT07219940
View directory record Official record
Conditions
Healthy Subjects, Exosome, Targeted Therapy
Interventions
SOB100
Drug
Lead sponsor
Shine-On Biomedical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 31, 2026, 5:20 AM EDT